Premium
Prognostic significance of serum p53 antibodies in patients with limited‐stage small cell lung cancer
Author(s) -
Zalcman Gérard,
Trédaniel Jean,
Schlichtholz Beata,
Urban Thierry,
Milleron Bernard,
Lubin Richard,
Meignin Véronique,
Couderc LouisJean,
Hirsch Albert,
Soussi Thierry
Publication year - 2000
Publication title -
international journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.475
H-Index - 234
eISSN - 1097-0215
pISSN - 0020-7136
DOI - 10.1002/(sici)1097-0215(20000120)89:1<81::aid-ijc13>3.0.co;2-i
Subject(s) - medicine , lung cancer , stage (stratigraphy) , multivariate analysis , population , gastroenterology , oncology , antibody , cancer , proportional hazards model , immunology , biology , paleontology , environmental health
p53 tumour suppressor gene alterations are one of the most frequent genetic events in lung cancer. A subset of patients with p53 mutation and cancer exhibited circulating serum anti‐p53 self‐antibodies (p53‐Ab). The prevalence of these antibodies in lung cancer is currently being analysed in a multicentric study. In a group of homogeneous SCLC patients, p53‐Ab were detected in 20/97 (20.6%) individuals. In this group of patients, Cox's multivariate analysis identified disease extent ( p = 0.022), WHO initial performance status greater than 0 ( p = 0.005), and the absence of a complete response after 6 months of treatment ( p < 0.0001) as independent prognostic variables, with p53‐Ab being of borderline significance ( p = 0.051). In the subset of limited‐stage SCLC patients, Cox's multivariate analysis found p53‐Ab ( p = 0.033), WHO initial performance status greater than 0 ( p = 0.028), and absence of a complete response ( p < 0.001) to be independent prognostic variables. Thus, actuarial analysis showed that patients with limited‐stage SCLC and p53‐Ab had a median survival time of 10 months, whereas limited‐stage SCLC patients without p53‐Ab had a 17‐month median survival time ( p = 0.014).Therefore, serum assay of p53‐Ab could help to identify a population of SCLC patients with an especially poor prognosis. This population could represent patients with tumours harboring aggressive p53 mutations. Int. J. Cancer (Pred. Oncol.) 89:81–86, 2000. © 2000 Wiley‐Liss, Inc.